Mechanism of Yanghe Pingchuan granules treatment for airway remodeling in asthma

LingYu Pan1,*, YanQuan Han1,*, YongZhong Wang1, QianQian Chen2, Ying Wu2, Yuan Sun2

1Grade 3 Preparation Laboratory of State Administration of TCM, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230031, China; 2Anhui University of Chinese Medicine, Hefei, Anhui 230031, China

*These authors contributed equally to this work

Purpose: Yanghe Pingchuan granules (YPG), a hospital preparation developed by The First Affiliated Hospital, Anhui University of Chinese Medicine, has been used for the clinical treatment of bronchial asthma (BA) for several decades. This study aimed to explore the mechanism of action of YPG in the treatment of BA.

Materials and methods: Male Sprague Dawley rats (n=60) were randomly divided into six groups (n=10 per group): control, a BA model, positive drug control (Guilong Kechuanning capsules; a proven effective treatment for BA), and model rats treated with a high, medium, or low dose of YPG. H&E staining was used to detect pathological changes in the bronchial tubes. The mRNA expression levels of PI3K, PKB, PCNA, and AR were determined by real-time PCR, and the protein levels of phospho- (p-)PI3K, p-PKB, p-PCNA, and p-AR were detected by Western blotting. ELISAs were used to detect the expression of PIP2, PIP3 IL-6, IL-8, IL-1β, and epinephrine (EPI).

Results: H&E staining demonstrated that BA can be ameliorated using YPG. Real-time PCR, Western blotting, and ELISA indicated that use of YPG decreased expression of the phosphatidylinositol 3-kinase (PI3K) signaling pathway and PCNA, and can also ameliorate the condition kidney Yang deficiency, which is associated with BA in Chinese traditional medicine.

Conclusion: YPG can attenuate BA therapeutically in a dose-dependent manner. The mechanism underlying its therapeutic effect comprises influences on three features that contribute to BA: the PI3K signaling pathway, cell proliferation, and “kidney-Yang deficiency”.

Keywords: bronchial asthma, YPG, PI3K/PKB signaling pathway, cell proliferation, kidney Yang deficiency

Introduction

Bronchial asthma (BA) is a type of allergic disease that seriously compromises the health of affected individuals worldwide. BA occurs among young adults and children, and is hard to differentiate from wheezing as a result of viral infections. In addition, it is necessary to take ethnic differences into account.1,2 The incidence of asthma increases almost every year, and has doubled since 1980.3

BA is a complex chronic disease characterized by variable airway limitation, airway remodeling, and airway hyper-reactivity.2 The pathogenesis of asthma has been considered to be caused by an imbalance of Th2-type and Th1-type lymphocytes.4 An increase of Th2 cells and release of cytokines are the two factors underlying airway injury.6 Currently, the primary pathogenesis of BA is considered to arise from an imbalance of Th-type lymphocytes, airway inflammation, airway remodeling, and the regulation of signaling pathways. Eventually, the airway inflammation leads to airway remodeling. Airway remodeling is a principal pathological feature of BA; therefore, it is necessary to study its pathogenesis.
Airway remodeling is associated with the abnormal proliferation of airway smooth muscle cells (ASMCs). The manifestations of airway remodeling include glandular hypertrophy, goblet cells, hyperplasia of smooth muscle fibers, and basement membrane thickening. ASMCs can secrete various factors, including matrix proteins, growth factors, cytokines, and other molecules, to modulate airway inflammation and promote airway remodeling. The activation and proliferation of ASMCs is influenced by numerous factors, including cytokines, growth factors, extracellular matrix proteins, and signaling pathways. Phosphoinositide 3-kinase (PI3K) signaling has a clear role in the proliferation of ASMCs, significantly influencing the regulation of ASMC proliferation. The PI3K pathway has essential functions in various inflammatory cells, including control of cell growth and survival, along with modulation of cytoskeleton remodeling. Upon activation, PI3K converts phosphatidylinositol (3,4) bisphosphate (PI (3,4) P2) to phosphatidylinositol (3,4,5) trisphosphate (PI (3,4,5) P3), which activates downstream signaling molecules with regulatory roles in cells. PKB is a serine/threonine protein kinase downstream of the PI3K signaling pathway. Once activated, PKB can accelerate the cell cycle and promote cell proliferation, PCNA can be used to assess the severity of airway remodeling.

In traditional Chinese medicine (TCM), a classical and characteristic concept is that of the use of the “same treatments for different diseases”. In TCM, asthma is considered to be caused, not only by the lungs, but also by the kidney; hence the condition kidney Yang deficiency is established as contributing to the disease. To translate the TCM concept of kidney Yang deficiency into modern medical concepts, it is necessary to clearly understand that the pathogenesis of asthma is strictly related to the function of the hypothalamo-pituitary-adrenal (HPA) axis. A decrease in HPA axis function may aggravate airway inflammation in asthma; however, studies of the role of the kidney in the pathogenesis of asthma remain very rare. In this investigation we detected changes in epinephrine (EPI) and adrenergic receptor (AR) levels during asthma, thereby verifying the presence of kidney Yang deficiency during asthma.

Yanghe Pingchuan granules (YPG) is a hospital preparation made at The First Affiliated Hospital, Anhui University of Chinese Medicine. YPG contains nine types of TCM, as follows:

1. *Ephedra sinica* Stapf., an antipyretic and expectorant;
2. *Rehmannia glutinosa* (Gaertn.) DC, which helps to increase the blood volume and enhances renal function;
3. *Inula japonica* Thunb., which eases coughing and acts as an expectorant;
4. *Morinda officinalis* F.C.How, which is used to treat impotence and nocturnal emission;
5. *Schisandra chinensis* (Turcz.) Baill., which strengthens the body by tonifying the heart and kidney;
6. *Sinapis alba* L., which warms the lungs, disperses phlegm, and can relieve “Qi” and pain;
7. *Draba nemorosa* L., an expectorant, which also promotes the discharge of urine to eliminate edema;
8. *Angelica sinensis* (Oliv.) Diels, used to regulate menstruation, relieve pain, and prevent cancer; and
9. *Platycodon grandiflorus* (Jacq.) A.DC., which helps to relieve coughs and expel phlegm.

YPG can improve kidney Yang deficiency and cure BA.

Over the last few decades, YPG has been used for effective clinical treatment of BA; however, the mechanism underlying its action is not precisely understood. This paper evaluated the effectiveness, practicality, and feasibility of YPG for treatment of asthma and its effects on three physiological processes: PI3K signaling, cell proliferation, and kidney Yang deficiency.

**Materials and methods**

**Ethics statement**

We purchased male Sprague Dawley (SD) rats from the Laboratory Animal Center, Medical University of Anhui Province. All experiments were subject to approval by the Committee on the Ethics of Animal Experiments of Anhui University of Chinese Medicine (Permit Number: 2014AH029-02). All experiments were in accordance with the following rules and regulations:

1. The “Regulations for the Administration of Affairs Concerning Experimental Animals” issued by the National Science and Technology Commission.
2. The “Implementation Rules for the Management of Medical Laboratory Animals” issued by the Ministry of Health of the People’s Republic of China.

All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

**Chemicals and instruments**

Egg albumin (Sigma Aldrich Co., St Louis, MO, USA, batch number: A5378), Guilong Kechuanning capsules (Guilong Pharmaceutical (Anhui) Co. Ltd., Ma’Anshan, China).
China, batch number: 150509); Yanghe Pingchuan granules (The First Affiliated Hospital, Anhui University of Chinese Medicine, batch number: 20161209).

**YPG preparation**
Herbal materials included *E. sinica*, *R. glutinosa*, *I. japonica*, *M. officinalis*, *S. chinensis*, *S. alba*, *D. nemorosa*, *A. sinensis*, and *P. grandiflorus*. After determination of the optimum extraction process, herbal materials were pulverized to a powder, vacuum dried at 70°C, then eight volumes of 80% ethanol were added twice for 1.5 h each to extract active components. The extract was then filtered, and filtrates concentrated under reduced pressure until there was no alcohol odor.

**Analysis of YPG by UPLC-PDA**
Analysis of YPG quality was carried out using a Waters Acuity ultra-performance liquid chromatography (UPLC) H-Class system, consisting of an autosampler, a quaternary pump, and an Acquity photo-diode array (PDA) detector. An Acquity UPLC hybrids of ethyl bridge (BEH) C18 column (100×2.1 mm, 1.7 μm) was used for all separations: column temperature=35°C; analysis time=22 min; flow rate=0.3 mL/min; injection volume=0.5 μL; and wavelength=254 nm. The mobile phase consisted of acetonitrile (A) and phosphoric acid (B). The gradient elution program was: 0–3 min (5%–18% A), 3–6 min (18%–21% A), 6–10 min (21%–25% A), 10–10.5 min (25%–50% A), 10.5–13 min (50%–75% A), 13–17 min (75%–80% A), 17–18 min (80%–90% A), 18–19 min (100%–5% A), and 19–22 min (5% A). Five reference substances were used for qualitative analysis: sinapine thiocyanate, ferulic acid, acteoside, aurocetin, and schisandrin. All reference substances were acquired from the National Institute for the Control of Drug and Biological Products (Beijing, China). Similarity Evaluation Software of Traditional Chinese Medicine Injection (National Pharmacopoeia Commission of China, Edition A, 2004) was used to analyze the results of UPLC chromatography.

**Animal experiments, establishment of a BA model, and sample collection**
After acclimatization for 1 week, SD rats were randomly divided into six groups (n=10 per group), as follows: healthy control, BA model, BA model treated with high (YPG H), medium (YPG M), and low (YPG L) dose YPG, and positive drug (Guilong Kechuanning capsule) control. On the first day, rats in the model, YPG H, YPG M, YPG L, and positive drug control groups were injected intraperitoneally with 10% egg albumin dissolved in 0.9% saline. After 2 weeks, all six groups (including the healthy control group) were aerosolized with 1% egg albumin dissolved in 0.9% saline five-times every 2 days, once a week, to induce BA. Hydrocortisone (1 mg/mL) was injected intraperitoneally on the 1st, 16th, 18th, 19th, 22nd, 26th, and 28th day, with doses of 1.0, 1.2, 1.4, 1.6, 2.0, 8.0, and 8.0 mL, respectively, to produce the kidney deficiency model.

On the 28th day after modeling, rats in the YPG H, YPG M, and YPG L groups were administered with YPG (14.76, 7.38, and 3.69 g/kg, respectively, once a day) by gavage. The positive control group received Guilong Kechuanning capsules by gavage. Control and model animals were administered with an equivalent amount of regular saline once a day for 2 weeks. After the final dose, animals were anesthetized by intraperitoneal injection of 2% pentobarbital sodium (40 mg/kg), and bronchial tissue collected in freezing tubes and stored at −80°C.

**H&E staining**
Right lungs were fixed, paraffin embedded, and sectioned. Changes in airway wall structure and pathological alterations of the bronchi and smooth muscles were observed by conventional H&E staining and analyzed using ImageJ software.

**PI3K, PKB, PCNA, and AR mRNA expression**
Trizol reagent was used to extract RNA from bronchial tissue samples. cDNA was synthesized by reverse transcription using 2 μg of total RNA as a template. β-actin was selected as an internal control. The relative expression levels of PI3K, PKB, PCNA, and AR mRNA were determined by quantitative fluorescence PCR (ABI7000 quantitative fluorescence monitor) at 50°C for 2 min, 95°C for 15 min, 95°C for 15 s, and 60°C for 1 min. The primers used are listed in Table 1.

**PI3K, PKB, PCNA, and AR protein expression**
Bronchial tissue samples were lysed in 1 mL of cell extraction buffer. Lysates were incubated in radio-immunoprecipitation assay buffer and kept at 4°C, for 2 h, followed by centrifugation at 12,000×g for 30 min at 4°C, and the supernatants collected. Total proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis on 8% gels, transferred onto polyvinylidene fluoride membranes, and blocked in TBST (plus 5% skim milk powder, pH 7.4, tris-buffered saline [TBS] with 0.24% Tween-20). Membranes were then incubated overnight at 4°C with the following primary antibodies: p-PI3K (Abcam, ab86714, 1:1,000), p-PKB (Abcam, ab81283,
1:5,000), p-PCNA (Abcam, ab92552, 1:3,000), p-AR (Abcam, ab3442, 1:1,000), and β-actin (Abcam, ab8226, 1:2,000). Blots were washed three-times for 15 min in TBST and treated with an horseradish peroxidase-conjugated polyclonal goat anti-rabbit antibody (Beyotime, A0208, 1:1,000) for 2 h at room temperature. Membranes were washed three-times for 10 min, and HRP substrate used to detect the HRP-secondary antibody bound to the proteins of interest, based on the manufacturer’s instructions. The p-PI3K, p-PKB, p-PCNA, and p-AR protein expression levels were standardized to those of β-actin.

Statistical analysis

Data are expressed as the mean±SD. Statistical analyses were performed using SPSS17.0 (SPSS, Chicago, IL, USA). One-way analysis of variance was performed for multiple-sample analyses. P<0.05 was considered to be statistically significant.

Results

Qualitative analysis of YPG by UPLC-PDA

YPG was first analyzed by UPLC-PDA, alongside mixed reference standard compounds. As shown in Figure 1, over 16 peaks were generated in 23 min. Comparisons of individual peak retention times with those of reference standard compounds identified five compounds, including sinapine thiocyanate (3), ferulic acid (5), acteoside (6), aurocetin (7), and schisandrin (11) in YPG; other peaks were unknown.

YPG treatment ameliorated BA in vivo

To explore the effect of YPG in BA, a model of BA was established, as described above. The results of histopathological

Table 1 Primer sequences

<table>
<thead>
<tr>
<th>Gene target</th>
<th>Sense primer (5’ to 3’)</th>
<th>Anti-sense primer (5’ to 3’)</th>
<th>Product length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI3K</td>
<td>ATACCTGATGTCGCTGACGC</td>
<td>AATCCCTGTCATCGTCTACC</td>
<td>110</td>
</tr>
<tr>
<td>PKB</td>
<td>ACTCATCCGAGACCAACACGAC</td>
<td>AGCCCGAAGTCCGTTATCCTT</td>
<td>241</td>
</tr>
<tr>
<td>PCNA</td>
<td>AGGGCCTGGTCGGGACATC</td>
<td>CCGACGGTATGGTCGAAG</td>
<td>117</td>
</tr>
<tr>
<td>AR</td>
<td>TTCTTCTGCGCCAACGTGGT</td>
<td>TTGAAGGCGAGTGGCGTA</td>
<td>101</td>
</tr>
<tr>
<td>β-actin</td>
<td>CAGCGGAACCGCTATTGATG</td>
<td>TCACCCACACTGTGCGCAACGA</td>
<td>300</td>
</tr>
</tbody>
</table>
evaluation of lung tissue samples from each of the six experimental groups (healthy control, BA model, YPG H, YPG M, YPG L, and positive control) are illustrated in Figure 2. In the healthy control group, there was no visible infiltration of inflammatory cells in the bronchus, the bronchial wall was smooth, the cells were arranged regularly, and the thickness of the soft muscle layer was even (Figure 2A). In contrast, a large number of eosinophils, monocytes, and lymphocytes infiltrated the bronchial tube wall in the model group. As shown in Figure 2B, a series of pathological changes were visible, including microvascular leakage, and goblet cell and airway epithelial cell hyperplasia. In addition, the smooth muscle layer thickened and the mucous membrane of the bronchial mucosa increased and extended. After treatment with YPG, infiltration of eosinophils, lymphocytes, and other inflammatory cells was significantly reduced; the thickness of the tube wall and the smooth muscle layer was close to that of the healthy control group; and the structures of the bronchial mucosa and trachea were improved (Figure 2C).

Compared with the healthy control group, the area to circumference ratio of the endobronchial tube and the rate of thickness to the boundary of smooth muscle in the model group were significantly increased ($P<0.01$). These results suggested inflammation of the bronchi and soft tissues (Table 2). After treatment with YPG, the ratio decreased, and the therapeutic effect was dose-dependent ($P<0.01$), with the effect of treatment in the YPG H group superior to those in the YPG M and L groups. Moreover, the effect of treatment in the YPG H group was similar to that observed in the positive control group.

### TIL-6/IL-8/IL-1β expression

To confirm the effect of treatment with YPG on BA, levels of IL-6, IL-8, and IL-1β were measured by ELISA (Figure 3). Compared with the healthy control group, the levels of IL-6, IL-8, and IL-1β were increased in the model group ($P<0.01$).

<table>
<thead>
<tr>
<th>Group</th>
<th>Area to circumference ratio of the endobronchial tube ($\mu m^2/\mu m$)</th>
<th>Rate of thickness to the boundary of smooth muscle ($\mu m^2/\mu m$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy control</td>
<td>5.24±0.35</td>
<td>2.46±0.20</td>
</tr>
<tr>
<td>Model</td>
<td>13.64±0.92</td>
<td>8.52±0.49</td>
</tr>
<tr>
<td>YPG H</td>
<td>6.84±1.20</td>
<td>4.24±0.89</td>
</tr>
<tr>
<td>YPG M</td>
<td>7.63±0.40</td>
<td>4.71±0.23</td>
</tr>
<tr>
<td>YPG L</td>
<td>8.88±3.44</td>
<td>6.34±1.33</td>
</tr>
<tr>
<td>Positive control</td>
<td>7.14±0.42</td>
<td>4.76±0.30</td>
</tr>
</tbody>
</table>

Notes: Data are presented as the mean±SD. n=8 per group. **P<0.01, vs healthy control group; ***P<0.01, vs model; group H= high-dose, M= middle-dose, L= low-dose.

Abbreviation: YPG, Yanghe Pingchuan granules.
In groups treated with YPG, levels of IL-6, IL-8, and IL-1β were substantially reduced, and the therapeutic effect was dose-dependent ($P<0.01$), with a superior effect observed in the YPG H group compared with the YPG M and L groups. The efficacy achieved in the YPG H group was similar to that observed in the positive control group. Together with the H&E staining results, these results indicate that YPG can markedly improve features of BA in this model.

YPG regulates ASMC proliferation through targeting the PI3K/PKB pathway

To determine whether YPG treatment effects PI3K/PKB signaling in the context of BA, we evaluated the protein expression of PI3K and PKB in bronchial tissue from rats in all experimental groups. As shown in Figures 4 and 5, compared with the control group, the protein levels of PI3K and PKB were significantly increased after treatment with YPG.
YPG (P<0.01), as were their mRNA levels. The inhibition effect on the PI3K pathway was not significant in the YPG L group; however, there were clear effects in the YPG H and L groups (P<0.01).

**Effect of YPG on PIP2 and PIP3 expression**
To further examine the effects of YPG on the PI3K/PKB signal pathway during treatment of BA, levels of the cytokines, PIP2 and PIP3, were monitored by ELISA. Compared with the healthy control group, levels of PIP2 and PIP3 were significantly increased in the model group (P<0.01; Figure 6). After YPG treatment, levels of PIP2 and PIP3 in the YPG-treated groups were decreased compared with the model group (P<0.01). The most marked therapeutic effect was observed in the YPG H group, which had similar levels of cytokines to those in the positive control group.

**Evaluation of EPI and AR expression**
To test whether the onset of asthma is associated with kidney Yang deficiency, levels of EPI and AR were detected by ELISA, real-time PCR, and Western blot. As shown in Figure 7, compared with the healthy control group, levels of EPI and AR were decreased in the model group (P<0.01). These data suggest that kidney function is decreased during asthma. After treatment with YPG, the expression levels of EPI and AR were significantly increased (P<0.01), and EPI and AR mRNA levels in rats from the YPG H and positive control groups were restored to levels similar to those in the
Pan et al.

healthy control group; however, AR protein levels were not restored by YPG treatment. These results indicate that YPG can improve kidney Yang deficiency.

Evaluation of PCNA expression

To test whether asthma is associated with abnormal cell proliferation, the expression of PCNA was detected by real-time PCR and Western blot. As shown in Figure 8, the expression of PCNA in the model group was significantly increased compared with the healthy control group ($P<0.01$), indicating that asthma is accompanied by abnormal cell proliferation. After treatment with YPG, levels of PCNA decreased significantly ($P<0.01$). A superior therapeutic effect was observed in the YPG H group compared with the YPG M and L groups, and treatment effects were dose-dependent.

Discussion

Asthma is an airway conduction disorder that responds to exogenous and endogenous stimuli in both children and adults. It is the most prevalent chronic respiratory disease, and resembles a complex syndrome, rather than a distinct disease. Asthma affects ~300 million peoples of all ages and ethnic groups, and from all countries, and is becoming a global health problem, leading to the deaths of 250,000 people annually. Asthma pathogenesis is complex, and involves a network of interacting factors at all levels and scales, from genetic to cellular, tissue, and organ. Airway remodeling is a primary cause of BA and a representative model of the condition. An increase in the number of ASMCs is a dominant structural change in asthma, and a crucial factor underlying airway remodeling and decreased lung function.

The proliferation of ASMCs, which is a critical feature of airway remodeling, is correlated with the PI3K signaling pathway. In non-asthmatic ASMCs, mitogens control growth via the phosphoinositide 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) signaling pathways. The PI3K family of proteins controls a wide variety of cellular...
functions, including proliferation, transcription, apoptosis, cell migration, glucose metabolism, and differentiation, via catalysis of the phosphorylation of the 3-OH position of phosphoinositides and generation of lipids. The PI3K family is divided into four classes; three of which have phosphorylated lipids as their primary targets, while the fourth category (mTOR, ATM, ATR, and DNA-PK) targets phosphorylated proteins. Growth factors and insulin can activate PI3K by targeting its catalytic membrane subunit close to its substrate (primarily PIP2). PKB contains a C-terminal pleckstrin homology (PH) domain, and binds to membrane-bound PIP3. PI3K can induce the activation of PKB in two steps. First, PIP3 recruits PKB to the cell membrane through binding to the PH domain of PKB, permitting its activation by PDK1. PDK1 contains a PH domain, binds to membrane-bound PIP3, and triggers its activation. Hyperactivity of PKB can promote cell growth, cell proliferation, and metabolism, along with resistance to hypoxia and migration.

PCNA is a necessary cofactor for a critical enzyme in the process of DNA synthesis, and the presence of PCNA significantly increases the rate of DNA synthesis; hence, cell proliferation can be estimated by measurement of PCNA expression. Airway remodeling, an essential feature of asthma, is due to abnormal proliferation of ASMCs, and an unusual increase in ASMCs may correlate with increased expression of PCNA.

In TCM, asthma is often associated with kidney Yang deficiency. “Chronic lung disease involving the kidney” and the “internal–external relationship between the lung and kidney” are both also essential concepts in TCM. These TCM concepts are based on the consequences of neuroendocrine disturbance and abnormal function of the HPA axis. Expression levels of EPI and AR can be used as markers of the function of the HPA axis; hence, changes in their levels can be used to evaluate the impact of kidney deficiency on asthma.

In this paper, we aimed to investigate the mechanism of action of YPG in treatment of asthma by evaluation of three relevant aspects: the PI3K signaling pathway, cell proliferation of cells (PCNA), and kidney Yang deficiency. The results of H&E staining and analysis of IL-6, IL-8, and IL-1β expression indicate that YPG has a therapeutic effect in BA. Moreover, UPLC analysis demonstrated that YPG contains five active ingredients: sinapine thiocyanate, ferulic acid, acteoside, auceretin, schisandrin. Data from Western-blotting, real-time PCR, and ELISAs indicate increased...
expression of PI3K, PKB, PIP2, and PIP3, suggesting that asthma results in enhanced activity of the PI3K pathway. Increased expression of the PI3K pathway can promote cell proliferation and differentiation. Therefore, the PI3K pathway appears to be a leading cause of airway remodeling, and is a potential target for treatment. After treatment with YPG, the levels of PI3K, PKB, PIP2, and PIP3 were significantly decreased, demonstrating that YPG affects airway remodeling through inhibiting the expression of the PI3K signaling pathway. Levels of the cell proliferation marker, PCNA, were elevated in the BA model and reduced after treatment with YPG. These results show that asthma is accompanied by abnormal cell proliferation, accompanied by changes in PCNA expression, indicating that abnormal cell proliferation can cause airway remodeling, and that inhibition of such proliferation by YPG can be used to treat airway remodeling in asthma. Levels of the markers of HPA axis activity and kidney Yang deficiency, EPI and AR, were markedly changed before and after asthma. These results demonstrate reduced function of the HPA axis in asthma, which may contribute to asthma pathogenesis. After treatment with YPG, the expression of EPI and AR was increased, suggesting that this preparation can stimulate the activity of the HPA axis, improve the symptoms of kidney Yang deficiency, and be used for treatment of asthma.

Conclusion
In conclusion, our study confirms that YPG can be used to treat asthma through blocking the PI3K/PKB pathway, inhibiting the abnormal proliferation of ASMCs, and ameliorating kidney Yang deficiency. This is the first report of a link between kidney Yang deficiency and asthma. The results of this investigation clearly suggest new approaches for asthma treatment by blocking the PI3K/PKB signaling pathway and ameliorating kidney Yang deficiency, and provide strong support for the clinical application of YPG.

Acknowledgments
LingYu Pan and YanQuan Han are considered co-first authors. This work was supported by grant KJ2015A124 from the Clinical Research Fund of the Anhui University of Chinese Medicine (The key projects of Natural Science Foundation of Anhui University), China. We thank Professor FeiFei Ding for English language editing.

Disclosure
The authors report no conflicts of interest in this work.

References